(526 days)
Not Found
No
The device description details a simple electronic circuit for pulsed shortwave therapy and there are no mentions of AI, ML, or related concepts in the summary.
Yes
The device is described as an "Adjunctive treatment of musculoskeletal pain" and the studies show that it treats pain.
No
The device description and intended use clearly state that it is a pulsed shortwave therapy device for adjunctive treatment of pain, not for diagnosing conditions.
No
The device description explicitly states it is a "pulsed shortwave therapy device" with "circuitry," an "antenna," a "signal generator circuit," and a "battery power supply," indicating it is a hardware device that delivers RF energy.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens taken from the human body (like blood, urine, or tissue) to provide information for diagnosis, monitoring, or screening.
- Device Description and Intended Use: The ActiPatch device is described as a pulsed shortwave therapy device that applies RF energy to the target tissue for the adjunctive treatment of musculoskeletal pain. It is applied externally to the body.
- Lack of Specimen Analysis: There is no mention of the device analyzing any biological specimens from the patient.
The device's function is to deliver therapeutic energy to the body, which falls under the category of therapeutic medical devices, not diagnostic ones.
N/A
Intended Use / Indications for Use
Adjunctive treatment of musculoskeletal pain related to: (1) plantar fasciitis of the heel; and (2) osteoarthritis of the knee.
Product codes
PQY, ILX
Device Description
The ActiPatch® device is a pulsed shortwave therapy device. The circuitry consists of low voltage (3 V) digital/analog electronics that control all timing functions to produce the therapeutic radiofrequency (RF) field, where the antenna is placed directly above the therapeutic site. This closed loop system of the antenna, low energy signal generator circuit, and battery power supply, transfers the RF energy to the target tissue as a localized therapy with no far field effects.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Superficial soft tissue (specifically plantar fasciitis of the heel and osteoarthritis of the knee)
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Over-The-Counter Use
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Two IRB approved double blind and placebo controlled randomized controlled trials were conducted in support of this premarket notification. Usability testing was conducted to support the OTC use of the device.
- The osteoarthritis of the knee study was a double blind randomized controlled study in 66 intent-to-treat patients, out of which 60 patients completed the four-week study. The primary effectiveness endpoints were improvements in pain level over the four weeks as measured by the before and after VAS score and WOMAC scores, and the primary safety endpoint was all treatment-related adverse events during the study.
- The plantar fasciitis study was a double-blind, multicenter, randomized, placebo-controlled study to evaluate the safety and effectiveness of the ActiPatch to reduce the pain level of patients diagnosed with plantar fasciitis. A total of 70 patients completed the study. The primary effectiveness endpoint was the daily morning (AM) VAS score, and the primary safety endpoint was all treatment-related adverse events during the 7-day study.
- Usability testing was conducted on 46 men and women over the age of 17 with a wide range of education levels. These subjects demonstrated use of the ActiPatch on either the knee, lower back, or shoulder.
Key Metrics
- Osteoarthritis of the knee study: 36% of the treatment group reported a clinically significant decrease in VAS pain, defined as a >30% decrease in pain, compared to 9% for the placebo group, and 18% of the treatment group reported a clinically significant decrease in total WOMAC pain, defined as a >30% decrease in pain, compared to 3% for the placebo group. In the treatment group, 26% stopped pharmacological therapy whereas in the placebo group 33% started a new pharmacological therapy during the study. No adverse events were recorded.
- Plantar fasciitis study: The results showed that the average reported pain reduction between the first day's AM pain score and the 7th day's AM pain score for the treatment group was 40% compared to 7% for the control group.
- Usability testing: The testing showed that lay users understand the indications for use and when not to use the device. In addition, the study showed that users understand how to turn the device on, place it correctly on the right part of the body, and how long to use the device.
Predicate Device(s)
ActiBand (K022404), Ivivi (K070541), Orthocor (K092044)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 890.5290 Shortwave diathermy.
(a)
Shortwave diathermy for use in applying therapeutic deep heat for selected medical conditions —(1)Identification. A shortwave diathermy for use in applying therapeutic deep heat for selected medical conditions is a device that applies to specific areas of the body electromagnetic energy in the radiofrequency (RF) bands of 13.56 megahertz (MHz) or 27.12 MHz and that is intended to generate deep heat within body tissues for the treatment of selected medical conditions such as relief of pain, muscle spasms, and joint contractures, but not for the treatment of malignancies.(2)
Classification. Class II (performance standards).(b)
Nonthermal shortwave therapy —(1)Identification. A nonthermal shortwave therapy is a prescription device that applies to the body pulsed electromagnetic energy in the RF bands of 13.56 MHz or 27.12 MHz and that is intended for adjunctive use in the palliative treatment of postoperative pain and edema of soft tissue by means other than the generation of deep heat within body tissues as described in paragraph (a) of this section.(2)
Classification: Class II (special controls). The device is classified as class II. The special controls for this device are:(i) Components of the device that come into human contact must be demonstrated to be biocompatible.
(ii) Appropriate analysis/testing must demonstrate that the device is electrically safe and electromagnetically compatible in its intended use environment.
(iii) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use. Non-clinical performance testing must characterize the output waveform of the device and demonstrate that the device meets appropriate output performance specifications. The output characteristics and the methods used to determine these characteristics, including the following, must be determined:
(A) Peak output power;
(B) Pulse width;
(C) Pulse frequency;
(D) Duty cycle;
(E) Characteristics of other types of modulation that may be used;
(F) Average measured output powered into the RF antenna/applicator;
(G) Specific absorption rates in saline gel test load or other appropriate model;
(H) Characterization of the electrical and magnetic fields in saline gel test load or other appropriate model for each RF antenna and prescribed RF antenna orientation/position; and
(I) Characterization of the deposited energy density in saline gel test load or other appropriate model.
(iv) A detailed summary of the clinical testing pertinent to use of the device to demonstrate the effectiveness of the device in its intended use.
(v) Labeling must include the following:
(A) Output characteristics of the device;
(B) Recommended treatment regimes, including duration of use; and
(C) A detailed summary of the clinical testing pertinent to the use of the device and a summary of the adverse events and complications.
(vi) Nonthermal shortwave therapy devices marketed prior to the effective date of this reclassification must submit an amendment to their previously cleared premarket notification (510(k)) demonstrating compliance with these special controls.
0
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
February 3, 2017
BioElectronics Corporation Andrew Whelan President 4539 Metropolitan Court Frederick, Maryland 21704
Re: K152432
Trade/Device Name: ActiPatch® Regulation Number: 21 CFR 890.5290 Regulation Name: Shortwave Diathermy Regulatory Class: Class II Product Code: PQY Dated: December 2, 2016 Received: December 2, 2016
Dear Mr. Whelan:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in
1
the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Michael J. Hoffmann -S
Carlos L. Peña, PhD, MS for Director Division of Neurological and Physical Medicine Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K152432
Device Name ActiPatch®
Indications for Use (Describe)
Adjunctive treatment of musculosketal pain related to: (1) plantar fasciitis of the heel; and (2) osteoarthritis of the knee
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
|X | Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Section 5: ActiPatch 510(k) Summary
-
- Submitter's Name:
BioElectronics Corporation
- Submitter's Name:
-
- Address: 4539 Metropolitan Court Frederick, MD 21704 United States Phone: 301-874-4890 Fax: 301-874-6935
Contact Person:
Andrew Whelan President and Chief Executive Officer
-
- Date Prepared:
December 1, 2016
- Date Prepared:
-
- Trade Name:
ActiPatch®
- Trade Name:
5. Common Name
Non-thermal Shortwave Therapy
-
- Product Classification: 21 CFR § 890.5290(b) Product code ILX
7. Predicate Devices:
ActiBand (K022404), Ivivi (K070541), Orthocor (K092044)
8. Description of Device:
The ActiPatch® device is a pulsed shortwave therapy device. The circuitry consists of low voltage (3 V) digital/analog electronics that control all timing functions to produce the therapeutic radiofrequency (RF) field, where the antenna is placed directly above the therapeutic site. This closed loop system of the antenna, low energy signal generator circuit, and battery power supply, transfers the RF energy to the target tissue as a localized therapy with no far field effects.
9. Intended Use:
Adiunctive treatment of musculoskeletal pain related to: (1) plantar fasciitis of the heel; and (2) osteoarthritis of the knee.
4
10. Standards:
ISO 13485:2003 Quality System Standard
ISO 13485:2012 Medical Devices: Quality Management Systems ISO 14155 Clinical investigation of medical devices for human subiects.
ISO 14971: 2012 Risk Management
ISO 10993-6:2009 Part 6 Evaluations of Medical Devices SOR/ 98-282 G D 207 & GD 210 Canadian MDR Quality Systems 93/42/EEC 2012/47/EC Council Directive
BS EN ISO 15223-1:2012 Labeling of Medical Devices
EN 1041:2008 Information Supplied with Medical Devices
EN 60601-1-2:2012 Electromagnetic Compatibility Requirements & Tests
EN 60601-1-11: 2010 Home Health Care Environment EN 60601 -1: 2006 Medical Electrical Equipment Requirements and
Tests
EN 60601-2-3: 2012 Short-Wave Therapy Equipment
EN 60601-2-10: 2001 Safety of Nerve and Muscle Stimulators MEDDEV 2.7.1 Rev. 3 Clinical Evaluation
MEDDEV 2.12-1 Rev.8 Vigilance System in Europe
MEDDEV 2.12/2 rev. 2 Post Market Clinical Follow-Up Studies
MEDDEV 12.2-2 Rev. 2 Post Market Surveillance
11. Summary of technological characteristics:
The ActiPatch® device has the following technological characteristics (TABLE 1). The ActiPatch operates at 27.12MHz shortwave frequency, pulsing at a 1000 pulses per second with a pulse width of 100psecs. The duty cycle is therefore 10%. The power source is a 3V battery (CR 2032), producing a peak spatial power density of 73 microWatts/cm².
Table 1. Technological characteristics of the ActiPatch® Shortwave Therapy Device
| Carrier frequency | 27.12MHz |
|---|---|
| Peak spatial power density | 73 microwatts/ cm² |
| Pulse rate | 1000 pulses per second |
| Pulsed on duration | 100 micro seconds |
| Power source | Battery CR2032 |
| Antenna size | 12cm or 6cm |
| Treatment area | 110cm² or 30cm² |
| Weight | 9.5 grams |
| Operation time (lifetime of battery) | 720 hours |
| Recommended Treatment Time | Minimum of 12 hours per day |
5
12. Substantial Equivalence:
| | BioElectronics
ActiPatch® | ActiBand
(K022404) | Ivivi
(K070541) | Orthocor
(K092044) |
|----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indication for
Use | Adjunctive
treatment of
musculoskeletal
pain related
to: (1) plantar
fasciitis of the
heel; and (2)
osteoarthritis of
the knee | Treatment of edema
Following
Blepharoplasty | Adjunctive use
in the palliative
treatment of
post-operative
pain and edema
in superficial
soft tissue. | Adjunctive use in
the palliative
treatment of
postoperative
pain and
edema in
superficial soft
tissue.
Temporary relief of
minor muscular and
joint aches and
pains associated
with over-exertion,
strains, sprains,
and arthritis. |
| Technology | Pulsed
Shortwave
Therapy (Non-
thermal
Diathermy) | Pulsed
Shortwave
Therapy (Non-
thermal Diathermy) | Pulsed
Shortwave
Therapy (Non-
thermal
Diathermy) | Pulsed Shortwave
Therapy (Non-
thermal Diathermy) |
| Product Code | ILX | ILX | ILX | ILX
IMD |
| Regulation | 21 CFR
890.5290(b) | 21 CFR 890.5290(b) | 21 CFR
890.5290(b) | 21 CFR
890.5290(b)
21 CFR 890.5710 |
| Classification
Name | Shortwave
diathermy | Shortwave diathermy | Shortwave
diathermy | Shortwave diathermy |
| Anatomical sites | Superficial soft
tissue | Superficial soft
tissue | Superficial soft
tissue | Superficial soft tissue |
| How energy is
coupled | Induction coil | Induction coil | Induction coil | Induction coil |
| Carrier
Frequency | 27.1 MHz | 27.1 MHz | 27.1 MHz | 27.1 MHz |
| Pulse duration | 100 µsecs | 100 µsecs | 2 ms | 2 ms |
| Pulse rate | 1000 Hz | 1000 Hz | 2 Hz | 2 Hz |
| Duty cycle | 10% | 10% | 0.4% | 0.4% |
| Power source | 3V DC
(1 X CR2032
Lithium Battery) | 3V DC (Battery) | 6V DC
(2 X CR2032
Lithium Battery)
(or) Mains | 3V - 4.2V DC
(Battery) |
| Antenna size
(treatment area) | 110 cm² | 65 cm² | 285 cm² | Undisclosed by
manufacturer |
| Averagespatial
power
density (RMS) | 4.4 µWatts/cm² | 4.4 µWatts/cm² | 4.4 µWatts/cm² | 4.4 µWatts/cm² |
| Specific
absorption rate
(W/kg) (Peak) | 0.0007 W/kg | 0.0007 W/kg | Undisclosed by
manufacturer | Undisclosed by
manufacturer |
| Operation time | 720 hours | 720 hours | Undisclosed by | Undisclosed by |
| (battery lifetime) | | | manufacturer | manufacturer |
| Recommended
treatment
duration (use
time) based on
clinical evidence | Minimum of 12
hours per day, up
to 24 hours per
day | Minimum of 12 hours
per day, up to 24
hours per day | Undisclosed by
manufacturer | Undisclosed by
manufacturer |
Substantial Equivalence Comparison Table
6
The table above compares the indication for use and technological characteristics of the ActiPatch with those of the predicate devices.
ActiPatch's technological features are almost identical to those of the ActiBand, with only slight differences that do not affect the technological performance of the device, such as the adoption of an ASIC microchip, compared to larger, discrete circuitry components (both active and passive) in the ActiBand, and a slightly larger antenna in the ActiPatch. The therapeutic effects of ActiBand® and ActiPatch® are due to the pulsed shortwave signal that is identical between the two devices.
ActiPatch's technological characteristics are also similar to those of the other predicates, for example, ActiPatch has the same carrier frequency as the Ivivi SofPulse device (K070541) and the OrthoCor Knee System (K092044), with only slight technological differences, for example in the pulse duration, pulse rate and duty cvcle.
The minor differences in the antenna size between ActiPatch and the predicate devices do not affect the average spatial power density levels. The performance data submitted in the premarket notification, including the electrical safety, electromagnetic safety, biocompatibility, and clinical data described in Section 13 below, show that any differences in technology do not adversely affect the safety and effectiveness of the ActiPatch compared to the predicates, and that the ActiPatch is at least as safe and effective as the predicates.
ActiPatch has the same intended use as the predicate devices, i.e., the application of electromagnetic energy to non-thermally treat pain. The difference in indications between the predicate products and ActiPatch, including the OTC use, does not result in a new intended use, and the available data on ActiPatch show that it is as safe and effective as the predicates.
7
13. Testing:
Non-Clinical/Performance Data:
Electrical safety, electromagnetic safety, biocompatibility testing, and testing in accordance with the special controls of the October 13, 2015 Final Reclassification Order for Non-thermal Shortwave Therapy devices was performed for the ActiPatch®.
The ActiPatch was tested for conformity to the following standards and was determined to conform to these standards:
- a. General Safety and Requirements Medical Equipment- IEC/EN 60601-1-2:2012
- b. General Safety and Requirements Medical Equipment- IEC 60601-1:2005+A1:2012
- c. General Safety and Requirements Medical Equipment-EN 60601-1:2006
Biocompatibility testing was conducted for the ActiPatch. The skin sensitization test performed in accordance with ISO 10993-10:2010 showed no evidence of an ActiPatch extract causing skin sensitization in guinea pigs. The skin irritation test conducted in accordance with ISO 10993-10:2010 demonstrated that gauze material saturated with extract from the ActiPatch showed no evidence of causing skin irritation in New Zealand white rabbits. The cytotoxicity test performed in accordance with ISO 10993-5:2009 showed that no observable in vitro cytotoxicity in L- 929 mouse fibroblast cells that were placed in contact with an extract prepared from ActiPatch.
The testing that was conducted in accordance with the special controls of the October 13, 2015 Final Reclassification Order demonstrated that the ActiPatch performs as intended under anticipated conditions of use. The testing determined and considered the peak output power; the pulse width; the pulse frequency: the duty cycle; the average measured output powered into the RF antenna/applicator; the specific absorption rates in a saline gel test load; the characterization of the electrical and magnetic fields in saline gel test load for each RF antenna and prescribed RF antenna orientation/position; and the characterization of the deposited energy density in saline gel test load.
Clinical Data:
Two IRB approved double blind and placebo controlled
8
randomized controlled trials were conducted in support of this premarket notification. Usability testing was conducted to support the OTC use of the device.
- d. The osteoarthritis of the knee study was a double blind randomized controlled study in 66 intent-to-treat patients, out of which 60 patients completed the four-week study. The primary effectiveness endpoints were improvements in pain level over the four weeks as measured by the before and after VAS score and WOMAC scores, and the primary safety endpoint was all treatment-related adverse events during the study. 36% of the treatment group reported a clinically significant decrease in VAS pain, defined as a >30% decrease in pain, compared to 9% for the placebo group, and 18% of the treatment group reported a clinically significant decrease in total WOMAC pain, defined as a >30% decrease in pain, compared to 3% for the placebo group. In the treatment group, 26% stopped pharmacological therapy whereas in the placebo group 33% started a new pharmacological therapy during the study. No adverse events were recorded.
- e. The plantar fasciitis study was a double-blind, multicenter, randomized, placebo-controlled study to evaluate the safety and effectiveness of the ActiPatch to reduce the pain level of patients diagnosed with plantar fasciitis. A total of 70 patients completed the study. The primary effectiveness endpoint was the daily morning (AM) VAS score, and the primary safety endpoint was all treatment-related adverse events during the 7-day study. The results showed that the average reported pain reduction between the first day's AM pain score and the 7th day's AM pain score for the treatment group was 40% compared to 7% for the control group.
- f. Usability testing was conducted on 46 men and women over the age of 17 with a wide range of education levels. These subjects demonstrated use of the ActiPatch on either the knee, lower back, or shoulder. TThe testing showed that lay users understand the indications for use and when not to use the device. In addition, the study showed that users understand how to turn the device on, place it correctly on the right part of the body, and how long to use the device.
Conclusion: The non-clinical and clinical data demonstrate that the ActiPatch is at least as safe and effective as its predicate devices, and can be used as an over-the-counter device.